CIP2A是一种预后不良因素，可作为甲状腺乳头状癌的诊断标志物。
CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma.
作者信息
Chao Ting-Ting, Maa Hung-Chune, Wang Cheng-Yi, Pei Dee, Liang Yao-Jen, Yang Yi-Feng, Chou Shuo-Jiun, Chen Yen-Lin
机构信息
Medical Research Center, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan R.O.C.
Department of Pathology, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan R.O.C.
出版信息
APMIS. 2016 Dec;124(12):1031-1037. doi: 10.1111/apm.12602. Epub 2016 Sep 21.
Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma. CIP2A has recently been described as a prognostic marker in many cancers. In this study, we assessed the value of this novel prognostic marker in PTC. A total of 178 surgical specimens of both benign and malignant thyroid tumors were collected. Immunohistochemical staining for CIP2A, HBME-1, galectin-3, and CK19 was performed. Western blotting for CIP2A was also performed. CIP2A was expressed in 85.3% of malignant tumors and 12.1% of benign tumors. ROC analysis showed that the AUC for CIP2A was higher than those for other tumor markers. Western blotting showed that CIP2A expression was higher in PTC than in other tumors. Poor progression-free survival was observed in the high-CIP2A expression group. High CIP2A expression is a poor prognostic factor and can be a diagnostic marker in PTC. The presence of any two of the three indicated makers (CIP2A, galectin-3, and HBME-1) is strongly correlated with the diagnosis of PTC.
甲状腺乳头状癌（PTC）是最常见的甲状腺癌类型。CIP2A最近被描述为多种癌症的预后标志物。在本研究中，我们评估了这种新型预后标志物在PTC中的价值。共收集了178例甲状腺良恶性肿瘤手术标本。进行了CIP2A、HBME-1、半乳糖凝集素-3和CK19的免疫组化染色。也进行了CIP2A的蛋白质印迹分析。CIP2A在85.3%的恶性肿瘤和12.1%的良性肿瘤中表达。ROC分析显示，CIP2A的曲线下面积高于其他肿瘤标志物。蛋白质印迹分析表明，PTC中CIP2A的表达高于其他肿瘤。在高CIP2A表达组中观察到无进展生存期较差。高CIP2A表达是一个不良预后因素，并且可以作为PTC的诊断标志物。三种指示标志物（CIP2A、半乳糖凝集素-3和HBME-1）中任意两种的存在与PTC的诊断密切相关。
Zotero 插件